IL315706A - Sirp-alpha fusion polypeptides with modified fc domains - Google Patents

Sirp-alpha fusion polypeptides with modified fc domains

Info

Publication number
IL315706A
IL315706A IL315706A IL31570624A IL315706A IL 315706 A IL315706 A IL 315706A IL 315706 A IL315706 A IL 315706A IL 31570624 A IL31570624 A IL 31570624A IL 315706 A IL315706 A IL 315706A
Authority
IL
Israel
Prior art keywords
domain
fusion polypeptide
modified
seq
sirpα
Prior art date
Application number
IL315706A
Other languages
English (en)
Hebrew (he)
Inventor
Jens-Peter Volkmer
Original Assignee
Bitterroot Bio Inc
Volkmer Jens Peter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitterroot Bio Inc, Volkmer Jens Peter filed Critical Bitterroot Bio Inc
Publication of IL315706A publication Critical patent/IL315706A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL315706A 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains IL315706A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323417P 2022-03-24 2022-03-24
PCT/US2023/064886 WO2023183892A1 (en) 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains

Publications (1)

Publication Number Publication Date
IL315706A true IL315706A (en) 2024-11-01

Family

ID=86054071

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315706A IL315706A (en) 2022-03-24 2023-03-23 Sirp-alpha fusion polypeptides with modified fc domains

Country Status (13)

Country Link
US (1) US20230365648A1 (https=)
EP (1) EP4499837A1 (https=)
JP (1) JP2025510774A (https=)
KR (1) KR20240162572A (https=)
CN (1) CN119546769A (https=)
AU (1) AU2023240361A1 (https=)
CA (1) CA3246192A1 (https=)
CL (1) CL2024002849A1 (https=)
CO (1) CO2024013909A2 (https=)
IL (1) IL315706A (https=)
JO (1) JOP20240212A1 (https=)
MX (1) MX2024011528A (https=)
WO (1) WO2023183892A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2816647T3 (es) 2012-01-17 2021-04-05 Univ Leland Stanford Junior Reactivos SIRP-alfa de alta afinidad
US10011660B2 (en) * 2012-04-30 2018-07-03 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
PL3575326T3 (pl) * 2012-12-17 2022-07-11 Pf Argentum Ip Holdings Llc Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
AU2016304794B2 (en) 2015-08-07 2021-07-15 ALX Oncology Inc. Constructs having a SIRP-alpha domain or variant thereof
CN116239698A (zh) * 2019-03-06 2023-06-09 江苏恒瑞医药股份有限公司 双功能融合蛋白及其医药用途
EP3976658A4 (en) * 2019-05-24 2023-06-07 Forty Seven, Inc. Regimes for co-administration of immunotherapeutic agents against c-kit and cd47
WO2020263830A1 (en) * 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use

Also Published As

Publication number Publication date
CO2024013909A2 (es) 2024-10-31
AU2023240361A1 (en) 2024-10-03
JOP20240212A1 (ar) 2024-09-29
CL2024002849A1 (es) 2025-05-23
KR20240162572A (ko) 2024-11-15
CA3246192A1 (en) 2023-09-28
WO2023183892A1 (en) 2023-09-28
EP4499837A1 (en) 2025-02-05
MX2024011528A (es) 2024-12-06
JP2025510774A (ja) 2025-04-15
US20230365648A1 (en) 2023-11-16
CN119546769A (zh) 2025-02-28

Similar Documents

Publication Publication Date Title
AU2002248184C1 (en) Molecules with extended half-lives, compositions and uses thereof
JP7811315B2 (ja) 補体関連疾患のための融合タンパク質構築物
KR20080005962A (ko) 인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체
US12338292B2 (en) CD47-CD38 bispecific antibodies
JP2024511642A (ja) 新規ｔｎｆｒ２結合分子
KR101576559B1 (ko) 종양 괴사인자―α 인간화 항체
US20240228650A9 (en) CD3/BCMA/CD38 Trispecific Antibodies
KR102602564B1 (ko) 인터루킨-6의 인간 수용체에 결합가능한 항체 또는 항원 결합성 단편
JP2024542823A (ja) アンタゴニスト抗ｎｐｒ１抗体およびその使用方法
US20230365648A1 (en) Sirp-alpha fusion polypeptides with modified fc domains
US20250257113A1 (en) Multivalent sirp-alpha fusion polypeptides
IL324435A (en) Anti-il1rap antibodies
JP2022545368A (ja) ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
US20240150489A1 (en) Cd47-cd38 bispecific antibodies
WO2024126833A1 (en) Cd47-il1rap bispecific antibodies
CN121175339A (zh) 抗fxi抗体及其用途
HK40108777A (zh) 仅有重链的抗bcma抗体
EA049156B1 (ru) Биспецифические антитела к cd47-cd38
EA052748B1 (ru) Антагонистические анти-npr1 антитела и способы их применения
WO2021051351A1 (zh) 一种分离的抗原结合蛋白及其用途
WO2021051352A1 (zh) 一种分离的抗原结合蛋白及其用途
EA046142B1 (ru) Антитела к trem-1 и их применения